[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pauls Stradins Clinical University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":125},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,58,79,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100625220","oxiclear-oxiris-cytokines-and-endotoxin-adsorption-rate-study-100625220",false,"NCT07419802","OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study","Endotoxin and Cytokine Adsorption Properties of the Oxiris Hemofilter in Septic Shock: Evaluation of Saturation Phenomena and Inflammatory Mediators' Clearance Capacity","OxiCLEAR","Inclusion Criteria (should meet all the criteria mentioned below):\n\n* Septic shock patient with a Dynamic scoring system of 6-8 points \u002FSeptic shock definition based on Sepsis-3: a vasopressor requirement to maintain a mean arterial pressure of 65 mmHg or greater and serum lactate greater than 2mmol\u002FL despite optimal (30ml\u002Fkg body weight) bolus fluid resuscitation\u002F\n* CVVH with AN69-polyethylenimine (Oxiris) membrane for at least 24 hours\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy\n* Known contraindications to citrate anticoagulation\n* High likelihood of death within 24 hours due to irreversible comorbidities (e.g., end-stage cardiac, pulmonary, or hepatic disease; hepatorenal syndrome; advanced uncontrolled malignancy)\n* Simultaneous treatment with another adsorption device during the study period","ALL","18 Years",{"count":20,"type":21},29,"ESTIMATED","OBSERVATIONAL","This study examines how well the Oxiris® hemofilter works over time in adults with septic shock who require continuous kidney support in the intensive care unit (ICU).\n\nSeptic shock is a severe form of infection that leads to organ failure, including acute kidney injury. Many people with septic shock require continuous renal replacement therapy (CRRT), a form of dialysis that runs continuously to support the kidneys. The Oxiris® hemofilter is a special type of CRRT filter designed not only to replace kidney function but also to remove harmful substances from the blood, including endotoxins from bacteria and inflammatory proteins (cytokines).\n\nAlthough Oxiris® is widely used, it is not known how long the filter continues to remove these substances effectively. Over time, the membrane of the filter may become filled with endotoxins and cytokines, which could reduce its ability to clean the blood. This study aims to determine whether and when this loss of adsorption occurs during a standard twenty-four-hour treatment period.\n\nAdults with septic shock who receive Oxiris® as part of routine ICU care will take part in this observational study. No experimental treatment will be given. Blood samples will be taken before and after the filter, and fluid leaving the filter will be collected, to measure how endotoxins and cytokines are removed over time.\n\nThe study will also assess how changes in filter performance relate to clinical markers such as blood pressure support, blood lactate levels, organ function scores, kidney recovery, and twenty-eight-day survival.\n\nThe results will help define the optimal timing for Oxiris® filter replacement and support more effective use of blood purification therapy in patients with septic shock.",[25,26,27,28],"Sepsis","Septic Shock","Blood Purification","Hemoadsorption",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Oxiris","blood purification","hemoadsorption","septic shock","saturation phenomena","Continuous renal replacement therapy (CRRT)","AN69-polyethylenimine membrane","Endotoxin adsorption","Cytokine adsorption","Membrane saturation","Mass balance","Inlet-outlet concentration gradient","Membrane fouling","Precision blood purification","Endotoxemia","RECRUITING","2026-02-16",{"date":48,"type":49},"2026-02-19","ACTUAL",{"date":51,"type":21},"2026-03-01",{"date":53,"type":21},"2027-09-01",{"name":55,"class":56},"Pauls Stradins Clinical University Hospital","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":57},"100558103","selective-coronary-revascularization-in-carotid-artery-disease-patients-after-carotid-revascularization-scorecad-trial-100558103","NCT06546761","Selective Coronary Revascularization in Carotid Artery Disease Patients After Carotid Revascularization (SCORECAD Trial)","Inclusion Criteria:\n\n1. Inform consent obtained before any study-related activities;\n2. Age above or equal to 50 years with symptomatic or asymptomatic critical carotid stenosis (symptomatic patients with at least Rankin III) which has been successfully revascularized by carotid endarterectomy or stenting within the past 14 days;\n3. Willing and able to undergo coronary CTA scan within 14 days of randomization and agrees to submission of CTA data set for HeartFlow FFRct analysis with results made available to treating physician.\n\nExclusion Criteria:\n\n1. Known CAD, history of MI, prior coronary revascularization (PCI or CABG);\n2. Patient underwent coronary angiography or coronary CTA before the randomization;\n3. Known history of 2nd or 3rd degree heart block; sick sinus syndrome; long QT syndrome;\n4. History of severe asthma, severe or bronchodilator-dependent Chronic obstructive pulmonary disease (COPD);\n5. Severe congestive heart failure (NYHA III or IV);\n6. Severe arrhythmia, prior pacemaker or internal defibrillator lead implantation;\n7. Impaired chronic renal function (EPI-GFR\\\u003C30ml\u002Fmin);\n8. Subjects with known anaphylactic allergy to iodinated contrast;\n9. Pregnancy or unknown pregnancy status in subject of childbearing potential;\n10. Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \\\u003C90 mmHg, or acute pulmonary edema;\n11. Any active, serious, life-threatening disease with a life expectancy of less than 2 years;\n12. Any active infection;\n13. Inability to comply with study procedures;\n14. Contraindication for guideline-guided long-term antiplatelet\u002Fanticoagulation regime after PCI\u002FCABG;\n15. Large neurologic deficit (Rankin scale \\>III);\n16. Participation in any interventional clinical study within 30 days prior to screening.","50 Years",{"count":66,"type":21},300,"The primary objective of this study is to determine whether among symptomatic and asymptomatic carotid artery stenosis (CAS) patients with no known coronary artery disease (CAD) who had undergone carotid artery revascularization (endarterectomy of stenting) a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.",[69,70],"Carotid Stenosis","Coronary Artery Disease","2024-08-06",{"date":73,"type":49},"2024-08-09",{"date":75,"type":49},"2024-06-25",{"date":77,"type":21},"2029-06-25",{"name":55,"class":56},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":89,"studyType":22,"phases":4,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":57},"100546358","latvian-early-atherosclerosis-registry-100546358","NCT06393894","Latvian Early Atherosclerosis Registry","A Prospective Registry to Assess Atherosclerosis Risk Factors and Their Relationship With Coronary Plaque Properties and Genetic Variations in Patients With Early Atherosclerosis of Unclear Origin.","Inclusion criteria:\n\n* Signed informed consent\n* Early atherosclerosis defined as coronary atherosclerosis in men aged \\\u003C55 years and women \\\u003C65 years\n* Coronary artery atherosclerosis with angiographically proven coronary vessel luminal stenosis ≥ 50% and ischaemia\n* Coronary artery atherosclerosis with planned revascularization\n* History of coronary artery revascularization (PTCA or coronary artery bypass surgery)\n* Coronary vessel suitable for NIRS pullback\n\nExclusion criteria:\n\n* Diabetes\n* Total cholesterol ≥7 mmol\u002Fl and\u002For LDL ≥ 5 mmol\u002Fl\n* family hypercholesterolemia\n* positive family history of early cardiovascular disease (myocardial infarction, sudden cardiac death or cardiovascular disease of first degree relatives at young age - men \\\u003C55 years, women \\\u003C65 years)\n* malignant or resistant hypertension ≥ 10 years\n* body mass index ≥40 kg\u002Fm 2 )\n* 20 or more pack years of smoking","65 Years",{"count":88,"type":21},100,"24 Months","Atherosclerosis and its complications are a global problem. There are several widely known and proven risk factors that promotes atherogenesis in the majority of patients. However, significant proportion of apparently healthy and young patients with cardiovascular disease but yet without recognized atherogenesis promoting risk factors can be observed in clinical practice. It highlights the need of new risk markers for early atherosclerosis diagnostics to prevent serious cardiovascular complications in these patients and in population in general. The interest in the negative impact of genetic variance, gene regulation on atherogenesis is growing. Therefore the purpose of this study is to analyze the impact of genetic variance and microRNA expression on early atherosclerosis development in the population of young, apparently healthy patients with coronary atherosclerosis. The primary hypothesis is that the group of patients with premature atherosclerosis have common genetic variations promoting early atherosclerosis development. The secondary hypothesis is that specific circulating microRNA expression (miR-126, miR-145 and miR-155) correlate with plaque lipid core by near infrared spectroscopy (NIRS) analysis.",[70,92],"Atherosclerosis, Coronary",[94,95,96,97],"Coronary artery disease","Early atherosclerosis","MicroRNA","Near infrared spectroscopy","2024-04-26",{"date":100,"type":49},"2024-05-01",{"date":102,"type":49},"2019-04-01",{"date":104,"type":21},"2030-12-31",{"name":55,"class":56},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":124,"locationsCount":57},"100535358","selective-coronary-revascularization-in-peripheral-artery-disease-patients-scorepad-trial-100535358","NCT06250790","Selective Coronary Revascularization in Peripheral Artery Disease Patients (SCOREPAD Trial)","Selective Coronary Revascularization in Peripheral Artery Disease Patients After Lower-extremity Revascularization (SCOREPAD Trial)","Inclusion Criteria:\n\n1. Inform consent obtained before any study-related activities;\n2. Age above or equal to 50 years with symptomatic lower extremity PAD (severe claudication or chronic limb-threatening ischemia, Rutherford 3,4,5) which has been successfully revascularized by open surgical or endovascular procedure within the past 14 days;\n3. Willing and able to undergo coronary CTA scan within 14 days of randomization and agrees to submission of CTA data set for HeartFlow FFRct analysis with results made available to treating physician.\n\nExclusion Criteria:\n\n1. Known CAD, history of MI, prior coronary revascularization (PCI or CABG);\n2. Patient underwent coronary angiography or coronary CTA before the randomization;\n3. Known history of 2nd or 3rd degree heart block; sick sinus syndrome; long QT syndrome;\n4. History of severe asthma, severe or bronchodilator-dependent Chronic obstructive pulmonary disease (COPD);\n5. Severe congestive heart failure (NYHA III or IV);\n6. Severe arrhythmia, prior pacemaker or internal defibrillator lead implantation;\n7. Impaired chronic renal function (EPI-Glomerular Filtration Rate (GFR)\\\u003C30ml\u002Fmin);\n8. Subjects with known anaphylactic allergy to iodinated contrast;\n9. Pregnancy or unknown pregnancy status in subject of childbearing potential;\n10. Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \\\u003C90 mmHg, or acute pulmonary edema;\n11. Any active, serious, life-threatening disease with a life expectancy of less than 2 years;\n12. Any active infection;\n13. Inability to comply with study procedures;\n14. Contraindication for guideline-guided longterm antiplatelet\u002Fanticoagulation regime after PCI\u002FCABG;\n15. Participation in any interventional clinical study within 30 days prior to screening.",{"count":114,"type":21},600,"The primary objective of this study is to determine whether among symptomatic Peripheral Arterial Disease (PAD) patients with no known Coronary Artery Disease (CAD) who had undergone lower-extremity revascularization, a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.",[117,70],"Peripheral Arterial Disease","2024-02-15",{"date":120,"type":49},"2024-02-16",{"date":118,"type":49},{"date":123,"type":21},"2029-02-15",{"name":55,"class":56},""]